Eagle Pharmaceuticals, Inc.

NasdaqGM:EGRX Stock Report

Market Cap: US$65.6m

Eagle Pharmaceuticals Past Earnings Performance

Past criteria checks 1/6

Eagle Pharmaceuticals's earnings have been declining at an average annual rate of -17%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 6.7% per year. Eagle Pharmaceuticals's return on equity is 4.7%, and it has net margins of 4.6%.

Key information

-17.0%

Earnings growth rate

-13.3%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate6.7%
Return on equity4.7%
Net Margin4.6%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Sep 21
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Jul 13
Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

Jun 21
Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Oct 27
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Oct 12

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Sep 27

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Aug 18

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Aug 15
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Aug 09

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Jul 06
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Apr 29
Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?

Dec 16
Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?

Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package

Jul 06
Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package

Eagle Pharmaceuticals: A Potential Reopening Play

Jun 16

Eagle Pharmaceuticals EPS misses by $0.49, misses on revenue

May 10

Eagle Pharma's Treakisym RTD + rituximab OK'd in Japan for large b-cell lymphoma

Apr 30

Eagle Pharmaceuticals (NASDAQ:EGRX) Could Easily Take On More Debt

Apr 15
Eagle Pharmaceuticals (NASDAQ:EGRX) Could Easily Take On More Debt

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 55% Above Its Share Price

Mar 25
Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 55% Above Its Share Price

Revenue & Expenses Breakdown
Beta

How Eagle Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:EGRX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 232581210336
31 Mar 23267-39337
31 Dec 22317368734
30 Sep 22298218231
30 Jun 22272237945
31 Mar 22246367843
31 Dec 21172-97551
30 Sep 2117967657
30 Jun 21189187538
31 Mar 21183147636
31 Dec 20188127931
30 Sep 2018658033
30 Jun 20177-58138
31 Mar 2019228040
31 Dec 19196147637
30 Sep 19204266931
30 Jun 19214426527
31 Mar 19216386333
31 Dec 18213326144
30 Sep 18204285848
30 Jun 18216306151
31 Mar 18207326842
31 Dec 17237527133
30 Sep 172711007738
30 Jun 17246977133
31 Mar 172371056030
31 Dec 16189815328
30 Sep 16127254022
30 Jun 169433525
31 Mar 1660-182827
31 Dec 156632028
30 Sep 1554-41923
30 Jun 1551-31722
31 Mar 155121421
31 Dec 1420-211219
30 Sep 1419-20917
30 Jun 1417-11414
31 Mar 1420-9311
31 Dec 1318-11410
30 Sep 1314-10510
30 Jun 1310-1489

Quality Earnings: EGRX has high quality earnings.

Growing Profit Margin: EGRX's current net profit margins (4.6%) are lower than last year (8.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: EGRX's earnings have declined by 17% per year over the past 5 years.

Accelerating Growth: EGRX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: EGRX had negative earnings growth (-47.6%) over the past year, making it difficult to compare to the Biotechs industry average (-8.9%).


Return on Equity

High ROE: EGRX's Return on Equity (4.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.